Chad Harman, CEOPsycheceutical is a bioscience company building on decades of psychedelic research. Dedicated to developing next-generation brain delivery technologies to treat mental health, the company strives to increase the safety and efficacy of psychedelics and unlock their therapeutic benefits for patients. Psycheceutical is developing two patented technologies focused on targeted drug delivery systems and precision dose formulations of psychedelics, beginning with ketamine. These novel delivery methods are designed to evade the psychogenic, hallucinogenic, and lethargic side effects that can hinder the exploration of psychedelics as an effective treatment strategy for mental health. Psycheceutical follows a ‘coopetition’ model, working with other companies developing psychedelic molecules that may require a delivery method.
“Our goal is to create unique formulations as well as share our patented technology with others in the industry to encourage the development of safe and effective medications that provide patients with a cost-effective treatment model,” says Chad Harman, CEO of Psycheceutical.
Targeted drug delivery to the brain can both enhance compound efficacy and mitigate side effects. Psycheceutical achieves this with its two patented technologies; the NeuroDirect™ Delivery System and Janus particles.
Developed by Dr. Ronald Aung-Din, Psycheceutical’s NeuroDirect™ Topical Delivery System enables patients to self-administer effective psychedelic medicine in a way that reduces the classic side effects of psychedelics, including hallucinations, nausea, and lethargy, to advance mental health treatment.
Patients can apply the topical cream on the back of their neck at the hairline to experience relief within minutes. It uses a non-systemic delivery technology that carries the compounds directly to the brain nerve endings to avoid the digestive system and reduce peripheral side effects.
NeuroDirect™’s efficacy was highlighted in patients with migraines. These patients experienced both pain reduction and anxiety relief within ten minutes of NeuroDirect™ application, a step up from traditional oral medications like Sumatriptan, which take 35 to 40 minutes.
NeuroDirect™ is convenient to use, allowing patients to relieve symptoms by applying the ketamine topical in any setting without the risk of over-medicating or intoxication. Whereas other ketamine treatments require hours of IV dosage in a clinic or supervision over telehealth, this at-home model will significantly reduce the cost of clinical care for both insurance companies and patients.
Psycheceutical’s next delivery method, Janus particles, is a cutting-edge systemic delivery technology developed by Dr. Anish Tuteja at the University of Michigan. Janus particles are multi-layered nanoparticles that deliver targeted doses of psychedelics across the blood-brain barrier to reduce the risk of peripheral side effects. Janus particles can also be formulated to deliver multiple medicines to the brain at different rates or in timed release.
Observational data from Dr. Aung-Din sheds light on the success of NeuroDirect™. Patients suffering from extreme PTSD, anxiety, and depression who never responded to traditional therapies or medications have shown remarkable and positive responses to a NeuroDirect™ ketamine formulation. Patients self-report a sudden calmness and persistent ability to refrain from attaching to their traumatic past and lead normal lives.
Our patents are unique in solving the challenges associated with psychedelics and will help innovate lifesaving mental health treatments with the direct and profound benefits of psychedelic medicines
Psycheceutical’s next delivery method, Janus particles, is a cutting-edge systemic delivery technology developed by Dr. Anish Tuteja at the University of Michigan. Janus particles are multi-layered nanoparticles that deliver targeted doses of psychedelics across the blood-brain barrier to reduce the risk of peripheral side effects. Janus particles can also be formulated to deliver multiple medicines to the brain at different rates or in timed release.
The remarkable manufacturing technology of Janus Particles plays an essential role in its immense capability to transform delivery technology. The patented process can make particles as small as 25 nanometers, which enables the effective delivery of compounds through the blood brain barrier into the brain.
Janus particles can also be manufactured into different shapes for specific usages. For instance, triangular-shaped particles have shown high efficacy in treating ovarian cancer, compared to similar sized-nanoparticles of a different shape.
“Our patents are unique in solving the challenges associated with psychedelics and will help innovate lifesaving mental health treatments with the direct and profound benefits of psychedelic medicines,” said Dr. Julian Bailes, Chief Medical Officer of Psycheceutical.
These incredible technologies are attributed to Psycheceutical’s team of expert neurosurgeons and neuroscientists like Dr. Julian Bailes and Dr. Aric Logsdon. Their cutting-edge research and knowledge in neuroanatomy and neurophysiology play a crucial role in our future development of these delivery technologies. Psycheceutical’s combination of innovative technologies and neurological experience helps to differentiate them in the bioscience market.
Psycheceutical’s focus on delivery technology upholds enormous potential in using different compounds to intervene in various neurological conditions beyond mental health. The team is currently exploring new opportunities for psychedelics to treat neurodegenerative disorders like Alzheimer’s and Parkinson’s disease as well as multiple sclerosis. Psycheceutical aims to bring more effective treatment approaches to patients worldwide by exploring the potential of psychedelics for numerous neurological conditions.
Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review
Monday, April 17, 2023
As Psycheceutical prepares to begin clinical trials for its novel NeuroDirect™ ketamine topical to treat PTSD, the company is named to Life Science Review's yearly Top Biotech Start-Up List
MIAMI - Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, was named in Life Sciences Review's Top 10 Biotech Startups for 2023. Psycheceutical earned recognition for its significant progress in developing innovative patented delivery technologies that are intended to increase the safety and efficacy of psychedelic compounds.
According to Life Sciences Review, "Psycheceutical's combination of innovative technologies and neurological experience helps to differentiate them in the bioscience market. Targeted drug delivery to the brain can both enhance compound efficacy and mitigate side effects. Psycheceutical achieves this with two patented technologies, the NeuroDirect™ topical delivery system and Janus particles. Psycheceutical's focus on delivery technology upholds enormous potential."
"We are proud to receive this distinction from Life Sciences Review and are honored to join the list of so many exciting biotech startups," said Psycheceutical CEO Chad Harman. "This type of award drives us to move as rapidly as possible into clinical phase testing and development so that more people can access the profound benefits of psychedelic medicine, with non-intimidating and cost-effective treatment options."
The company's novel NeuroDirect™ ketamine topical cream to treat PTSD has already shown positive pre-clinical results. Data from a recently published study in Drug Development and Delivery Journal supports the potential of NeuroDirect ketamine topical cream as an improved treatment for PTSD. In the study of 100 patients who didn't respond to traditional therapies, more than 80% trying NeuroDirect ketamine topical found it effective at treating their PTSD symptoms. "Discernible improvement[s] in anxiety, depression, paranoia and unrealistic fear, focusing issues, cloudy thinking, neuro¬pathic pain, and other such symptoms were noted within 8-10 minutes of topical drug application. No psychogenic effects, such as hallucinations or dissociative phenomena, were experienced by any patient. To the contrary, patients indicated their thought processes were clearer, more focused, and that they were more keenly aware of surroundings."
Psycheceutical's unique delivery method for psychedelic compounds has caught the attention of industry trailblazers like Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). "I've been working in psychedelics for more than 40 years, and it's rare for me to come across something unique like the NeuroDirect topical cream that is currently being developed by Psycheceutical with the goal of delivering a psychedelic compound without a psychedelic experience or negative side effects," noted Doblin." Psycheceutical recently announced plans to begin clinical trials in Q2 in Australia for its NeuroDirect ketamine topical cream as a treatment for PTSD. "I'm curious to learn about the results of Psycheceutical's upcoming clinical trials in Australia and to further evaluate this potential treatment. I look forward to reviewing more research data," said Doblin. "Sometimes the biggest breakthroughs are right under our noses."
